Olmesartán/Amlodipino/Hidroclorotiazida Normon (Olmesartan Medoxomil, Amlodipine, Hydrochlorothiazide)

Olmesartan is an angiotensin‑II receptor blocker that selectively blocks the AT‑1 receptor, preventing angiotensin‑II‑mediated vasoconstriction and aldosterone release. This results in relaxed blood vessels and reduced sodium‑water retention, contributing to lower blood pressure when combined with the other two agents.

The specific dose of this combination tablet is determined by the prescribing clinician based on the patient’s blood‑pressure level, response to therapy, and overall health profile. Physicians adjust the dose to achieve target blood‑pressure goals while monitoring safety.

Use of this combination is contraindicated during the second and third trimesters of pregnancy because of potential harm to the fetus. It should be used only if clearly needed in the first trimester. Breastfeeding mothers should consult a healthcare professional, as the drugs may pass into breast milk.

To place an order, visit the product page on gnhindia.com, submit an enquiry with the required quantity, and provide institutional or trade credentials. GNH India works with hospitals, pharmacies and procurement teams worldwide, responding with pricing, availability, shipping details and any necessary import documentation.

Compared with single‑agent therapy, this triple‑component tablet offers convenience and synergistic blood‑pressure reduction by targeting three mechanisms: angiotensin‑II blockade, calcium‑channel mediated vasodilation, and thiazide‑type diuresis. It can simplify regimens and improve adherence versus taking three separate pills, while providing comparable efficacy to other combination products.

Store the tablets at ambient temperature, below 25 °C, in the original packaging to protect them from moisture and light. Keep the container tightly closed and out of reach of children.

The medication is taken orally, usually once daily, with or without food, as directed by the prescribing clinician. Patients should swallow the tablet whole with a glass of water and follow any specific timing instructions provided by their healthcare provider.

Serious risks include severe hypotension, acute kidney injury, significant electrolyte imbalances such as hyper‑kalemia, and rare cases of angio‑edema. Patients should seek immediate medical attention if they experience swelling of the face or throat, sudden dizziness, or marked changes in urine output.

The combination should be avoided in patients with known hypersensitivity to any component, those with severe renal impairment, pregnant women in the second or third trimester, and individuals with a history of angio‑edema related to angiotensin‑II receptor blockers.